Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF alpha monoclonal antibodies

D Moshous1,2,3*, I Meyts4, S Fraitag2,5, C Janssen6, M Debré1,2, F Suarez2,7, J Toelen4, K De Boeck4, T Roskams6, A Deschildre8, C Picard1,2,3,9, C Bodemer2,10, C Wouters4, A Fischer1,2,3

From 18th Pediatric Rheumatology European Society (PReS) Congress Bruges, Belgium. 14-18 September 2011

Background
Cartilage-hair hypoplasia (CHH) is a rare autosomal recessive disorder characterized by short-limbed skeletal dysplasia. Some patients also develop defects in cell-mediated immunity and antibody production. Granulomatous inflammation has been described in patients with various forms of primary immunodeficiencies but, to date, has not been reported in patients with Cartilage-hair hypoplasia.

Aims
To describe granulomatous inflammation as a novel feature in patients with CHH, assess associated immunodeficiency and evaluate treatment options.

Methods
In a retrospective, observational study, we collected clinical data on 21 patients with CHH in order to identify and further characterize individuals with granulomatous inflammation.

Results
Four unrelated patients with CHH (with variable degrees of combined immunodeficiency) developed epithelioid cell granulomatous inflammation in the skin and visceral organs. Anti Tumor necrosis factor alpha monoclonal antibody therapy in 3 of these patients led to significant regression of granulomas. However, one treated patient developed fatal progressive multifocal leukoencephalopathy due to the JC polyomavirus. In two patients, immune reconstitution after allogeneic hematopoietic stem cell transplantation led to the complete disappearance of granulomas.

Conclusion
To the best of our knowledge, this is the first report of granulomatous inflammation in patients with CHH. Although Tumor necrosis factor alpha antagonists may effectively suppress granulomas, the risk of severe infectious complications limits their use in immunodeficient patients.

Author details
1Department of Pediatric Immunology and Hematology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants-Malades, Paris, France.
2Université Paris Descartes, Faculté de Médecine de l’Université René Descartes, Institut Fédératif de Recherche Necker Enfants-Malades (IFR94), Paris, France.
3Institut National de la Santé et de la Recherche Médicale, Unité U768, Laboratoire du Développement Normal et Pathologique du Système Immunitaire, Paris, France.
4Pediatric Immunology and Rheumatology, University Hospital Gasthuisberg, Leuven, Belgium.
5Department of Pathology, Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Maladies, Paris, France.
6Department of Pathology, University Hospital Gasthuisberg, Leuven, Belgium.
8Unité de pneumologie pédiatrique, Hôpital Jeanne de Flandre, Centre Hospitalier Régional, Universitaire, Lille, France.

Published: 14 September 2011